{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:57:44Z","timestamp":1794412664975,"version":"4.9.0"},"reference-count":47,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Astra - Zeneca","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Sillajen","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"the Intramural Research Program of the NIH, NCI","award":["BC 011343"],"award-info":[{"award-number":["BC 011343"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,12,30]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oncolytic immunotherapy represents a unique therapeutic platform for the treatment of cancer. Here, we evaluated the safety and efficacy of the combination of pexastimogene devacirepvec (PexaVec) plus durvalumab (anti-programmed death ligand 1) with and without tremelimumab (anti-cytotoxic T-lymphocyte associated protein 4) in patients with standard chemotherapy refractory mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) in a phase I\/II trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Adult patients with histologically confirmed advanced pMMR mCRC, who had progressed on at least two prior lines of systemic chemotherapy were studied in four cohorts. Patients received four doses of PexaVec IV at a dose of 3\u00d710\n                      <jats:sup>8<\/jats:sup>\n                      plaque forming units (pfu) (dose level 1) or 1\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \u2009pfu (dose level 2) every 2 weeks. Twelve days after the first PexaVec administration, patients received either 1500\u2009mg of durvalumab every 28 days alone or an additional single dose of 300\u2009mg tremelimumab on day 1. Responses were assessed every 8 weeks by CT or MRI. AEs were recorded. The primary endpoints were safety and feasibility. Secondary endpoints included progression-free survival (PFS) and overall survival. Paired tumor samples and peripheral blood were collected to perform immune monitoring.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-four patients with mCRC enrolled on to the study: 16 patients in the PexaVec\/durvalumab cohorts and 18 patients in the PexaVec\/durvalumab\/tremelimumab cohorts. Overall, the combination of PexaVec plus immune checkpoint inhibitors did not result in any unexpected toxicities. Most common toxicities observed were fever and chills after PexaVec infusion. Two cases of grade 3 colitis, one case of a grade 2 myositis and one case of grade 3 hypotension resulted in discontinuation of immune checkpoint inhibitor and PexaVec treatment, respectively. The median PFS in the PexaVec\/durvalumab\/tremelimumab cohorts was 2.3 months (95%\u2009CI: 2.2 to 3.2 months) vs 2.1 months (95%\u2009CI: 1.7 to 2.8 months; p=0.57) in the PexaVec\/durvalumab cohorts. Flow cytometry analysis of peripheral blood mononuclear cells revealed an increase in Ki67\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells on treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PexaVec in combination with durvalumab and tremelimumab is safe and tolerable. No unexpected toxicities were observed. The combination of PexaVec\/durvalumab\/tremelimumab demonstrated potential clinical activity in patients with pMMR mCRC, but further studies are needed to identify the predictive biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03206073\">NCT03206073<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2022-005640","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T10:20:22Z","timestamp":1675851622000},"page":"e005640","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":75,"title":["Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03206073","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03860272","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5558-2744","authenticated-orcid":false,"given":"Cecilia","family":"Monge","sequence":"first","affiliation":[{"name":"Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-0050","authenticated-orcid":false,"given":"Changqing","family":"Xie","sequence":"additional","affiliation":[{"name":"Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Myojin","sequence":"additional","affiliation":[{"name":"Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Coffman","sequence":"additional","affiliation":[{"name":"Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna Mabry","family":"Hrones","sequence":"additional","affiliation":[{"name":"Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Wang","sequence":"additional","affiliation":[{"name":"Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford J","family":"Wood","sequence":"additional","affiliation":[{"name":"Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center & Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot B","family":"Levy","sequence":"additional","affiliation":[{"name":"Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center & Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa","family":"Juburi","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M","family":"Hewitt","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3442-4453","authenticated-orcid":false,"given":"David E","family":"Kleiner","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D","family":"Figg","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Redd","sequence":"additional","affiliation":[{"name":"Radiology and Imaging Sciences, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Homan","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Cam","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-4471","authenticated-orcid":false,"given":"Benjamin","family":"Ruf","sequence":"additional","affiliation":[{"name":"Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin G","family":"Duffy","sequence":"additional","affiliation":[{"name":"Mater Misericordiae University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0806-2535","authenticated-orcid":false,"given":"Tim F","family":"Greten","sequence":"additional","affiliation":[{"name":"Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"},{"name":"Liver Cancer Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"2025100314301793000_11.2.e005640.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"2025100314301793000_11.2.e005640.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414325"},{"key":"2025100314301793000_11.2.e005640.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3245"},{"key":"2025100314301793000_11.2.e005640.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0106"},{"key":"2025100314301793000_11.2.e005640.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x"},{"key":"2025100314301793000_11.2.e005640.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.03.005"},{"key":"2025100314301793000_11.2.e005640.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2025100314301793000_11.2.e005640.8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"2025100314301793000_11.2.e005640.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2006.05.008"},{"key":"2025100314301793000_11.2.e005640.10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2545"},{"key":"2025100314301793000_11.2.e005640.11","doi-asserted-by":"publisher","DOI":"10.2174\/138920112800958922"},{"key":"2025100314301793000_11.2.e005640.12","first-page":"8751","article-title":"Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes","volume":"61","author":"McCart","year":"2001","journal-title":"Cancer Res"},{"key":"2025100314301793000_11.2.e005640.13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2687"},{"key":"2025100314301793000_11.2.e005640.14","doi-asserted-by":"publisher","DOI":"10.2174\/156652308784049363"},{"key":"2025100314301793000_11.2.e005640.15","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.109"},{"key":"2025100314301793000_11.2.e005640.16","doi-asserted-by":"publisher","DOI":"10.1038\/nature10358"},{"key":"2025100314301793000_11.2.e005640.17","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1126\/science.abk3436","article-title":"Oncolytic virotherapy as immunotherapy","volume":"374","author":"Melcher","year":"2021","journal-title":"Science"},{"key":"2025100314301793000_11.2.e005640.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2025100314301793000_11.2.e005640.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0913291107"},{"key":"2025100314301793000_11.2.e005640.20","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2375"},{"key":"2025100314301793000_11.2.e005640.21","unstructured":"The picard toolkit. 1.119 ed. n.d. Available: https:\/\/broadinstitute.github.io\/picard\/"},{"key":"2025100314301793000_11.2.e005640.22","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts356"},{"key":"2025100314301793000_11.2.e005640.23","doi-asserted-by":"publisher","DOI":"10.14806\/ej.17.1.200"},{"key":"2025100314301793000_11.2.e005640.24","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-019-0655-5","article-title":"Correction to: molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-Seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"key":"2025100314301793000_11.2.e005640.25","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz363"},{"key":"2025100314301793000_11.2.e005640.26","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu170"},{"key":"2025100314301793000_11.2.e005640.27","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp324"},{"key":"2025100314301793000_11.2.e005640.28","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu314"},{"key":"2025100314301793000_11.2.e005640.29","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btv566"},{"key":"2025100314301793000_11.2.e005640.30","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2514"},{"key":"2025100314301793000_11.2.e005640.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-018-0051-x"},{"key":"2025100314301793000_11.2.e005640.32","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw227","article-title":"VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research","volume":"44","author":"Lai","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2025100314301793000_11.2.e005640.33","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol"},{"key":"2025100314301793000_11.2.e005640.34","doi-asserted-by":"publisher","DOI":"10.1101\/gr.239244.118"},{"key":"2025100314301793000_11.2.e005640.35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00262-019-02299-8","article-title":"The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma","volume":"68","author":"Agdashian","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2025100314301793000_11.2.e005640.36","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.celrep.2019.06.049","article-title":"Comprehensive immune monitoring of clinical trials to advance human immunotherapy","volume":"28","author":"Hartmann","year":"2019","journal-title":"Cell Rep"},{"key":"2025100314301793000_11.2.e005640.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.11.002"},{"key":"2025100314301793000_11.2.e005640.38","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3089"},{"key":"2025100314301793000_11.2.e005640.39","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1158\/2326-6066.CIR-21-0171","article-title":"Neoadjuvant intravenous oncolytic vaccinia virus therapy promotes anticancer immunity in patients","volume":"10","author":"Samson","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2025100314301793000_11.2.e005640.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8"},{"key":"2025100314301793000_11.2.e005640.41","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.04.453","article-title":"LBA O-9 botensilimab, a novel innate\/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer","volume":"33","author":"Bullock","year":"2022","journal-title":"Annals of Oncology"},{"key":"2025100314301793000_11.2.e005640.42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239023","article-title":"Exploring the potential use of a PBMC-based functional assay to identify predictive biomarkers for anti-PD-1 immunotherapy","volume":"21","author":"Bacot","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025100314301793000_11.2.e005640.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.02.020."},{"key":"2025100314301793000_11.2.e005640.44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803903"},{"key":"2025100314301793000_11.2.e005640.45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1705327114"},{"key":"2025100314301793000_11.2.e005640.46","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00106","article-title":"Immune system, friend or foe of oncolytic virotherapy?","volume":"7","author":"Filley","year":"2017","journal-title":"Front Oncol"},{"key":"2025100314301793000_11.2.e005640.47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002086","article-title":"Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy","volume":"9","author":"Shin","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:30:26Z","timestamp":1759527026000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,8]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/jitc-2022-005640"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005640","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}